<DOC>
	<DOCNO>NCT01061177</DOCNO>
	<brief_summary>This study ass efficacy safety nilotinib adult patient newly diagnose Philadelphia chromosome positive/BCR-ABL positive chronic myeloid leukaemia chronic phase . The aim study confirm rate complete molecular remission ( CMR ) nilotinib newly diagnose CML chronic phase patient pan-European population use EUTOS standardized laboratory .</brief_summary>
	<brief_title>Nilotinib Newly Diagnosed Adult Philadelphia Chromosome &amp; /or BCR-ABL Positive Chronic Myeloid Leukaemia Chronic Phase</brief_title>
	<detailed_description />
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<criteria>Patients diagnosis CPCML cytogenetic confirmation Philadelphia ( Ph ) chromosome Ph negative case patient variant translocation BCRABL positive multiplex PCR also eligible WHO performance status 02 Laboratory assessment within normal limit Written inform consent prior study procedure perform Known impaired cardiac function History acute chronic pancreatitis Impaired gastrointestinal function disease may alter absorption study drug Concomitant medication potential QT prolongation , know interact CYP450 isoenzymes ( CYP3A4 , CYP2C9 , CYP2C8 ) Patients undergone major surgery â‰¤ 2 week prior start study drug recover side effect therapy Patients pregnant breast feeding , female reproductive potential employ effective method birth control . Female patient must agree employ effective barrier method birth control throughout study 3 month follow discontinuation study drug Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>myeloid</keyword>
	<keyword>myelogenous</keyword>
	<keyword>chronic BCR-ABL positive</keyword>
	<keyword>Nilotinib</keyword>
	<keyword>Philadelphia chromosome</keyword>
	<keyword>CML chronic phase</keyword>
</DOC>